KR950000693A - 프로펜산 유도체 - Google Patents
프로펜산 유도체 Download PDFInfo
- Publication number
- KR950000693A KR950000693A KR1019940014602A KR19940014602A KR950000693A KR 950000693 A KR950000693 A KR 950000693A KR 1019940014602 A KR1019940014602 A KR 1019940014602A KR 19940014602 A KR19940014602 A KR 19940014602A KR 950000693 A KR950000693 A KR 950000693A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- following general
- general formula
- formula
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Saccharide Compounds (AREA)
Abstract
본 발명은 다음 일반식(Ⅰ):
(식에서 A는 방향족 고리를 나타내고, R1은 아릴 등을 나타내고, R2,R3및 R4는 각각 수소, 저급 알킬 등을 나타내고, R7및 R8은 각각 저급 알킬 등을 나타낸다)으로 규정되는 아데노신 Al 길항작용을 나타내는 신규한 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (11)
- 다음 일반식(Ⅰ)으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적을 허용가능한 염.식에서 A는 방향족 고리를 나타내고, X,Y 및 Z는 각각 산소, 황, 질소 또는 탄소를 나타내고, R1은 임의로 치환된 아릴 또는 임의로 치환된 헤테로아릴을 나타내고, R2,R3및 R4는 동일하거나 상이할 수 있고 각각 수소, 저급 아릴, 저급 알켄일, 저급 알킨일 또는 식 -W-Q[식에서 W는 저급 알킬에서 유도된 기를 나타내고, Q는 임의로 치환된 아릴, 임의로 치환된 헤테로아릴, 시클로알킬, 시아노, 히드록실, 저급 알콕시, 아실옥시; 카르복실 또는 식 -NR9R10(식에서 R9및 R|10은 동일하거나 상이할 수 있고 각각 수소, 저급 알킬, 아실, 카르바모일 또는 알킬카르바모임을 나타내거나, 또는 선택적으로 R9및 R10은 그들이 결합되는 질소원자와 함께 고리모양 기를 나타낼 수 있다)으로 표시되는 기를 나타낸다]로 표시되는 기를 나타내고, R5및 R6은 상이할 수 있고 각각 수소 또는 저급 알킬을 나타내고, B는 산소 또는 황을 나타내고, R7및 R8은 동일하거나 상이할 수 있고 각각 수소, 저급 알킬, 저급 알콕시, 임의로 치환된 아릴, 임의로 치환된 아릴알킬, 임의로 치환된 헤테로알킬, 임의로 치환된 헤테로아릴알킬, 임의로 보호된 카르복시알킬, 다음 일반식:(식에서 R11은 수소, 저급 알킬, 임의로 치환된 아릴, 임의로 치환된 아릴알킬 또는 임의로 치환된 헤테로아릴을 나타내고, R12는 수소, 히드록실, 저급 아릴, 저급 알콕시, 임의로 보호된 카르복실, 임의로 치환된 아미노, 임의로 치환된 아일, 임의로 치환된 헤테로아릴, 임의로 치환된 아릴알킬 또는 임의로 치환된 헤테로아릴 알킬을 나타내고, R13은 수소, 히드록실, 저급 알킬, 저급 알콕시, 임의로 치환된 아릴 또는 임의로 치환된 헤테로아릴을 나타낸다)으로 표시되는 기, 또는 식 -V-E[식에서 V는 식 -CO-로 표시되는 기, 식 -(CH2)-로 표시되는 기 또는 다음 식:(식에서 R14는 임의로 치환된 아릴 또는 임의로 치환된 헤테로아릴을 나타내고, m은 0 또는 1의 정수를 나타낸다)으로 표시되는 기를 나타내고, E는 임의로 치환된 아릴 또는 임의로 치환된 헤테로아릴을 나타낸다]로 표시되는 기를 나타내거나, 또는 선택적으로 R7및 R8은 그들이 결합되는 질소원자와 함께, 치환될 수 있는 고리모양 기를 나타낼 수 있고, 단, (1) X,Y 및 Z중 1 내지 3개가 질소원자이고 질소원자중 하나 또는 전부가 그 인접원자중 하나에 이중결합을 통해 각각 결합되는 경우 또는 (2) X,Y 및 Z 중 하나가 질소이고 그들중 다른 하나가 산소 또는 황인 경우에는, 해당 X,Y 및/또는 Z는 그 각각의 치환기 R2,R3및/또는 R4를 가지지 않고 X,Y 및 Z중 적어도 하나는 치환되지 않는 것을 조건으로 한다.
- 제 1 항에 있어서, 다음 일반식으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염.식에서 R1,R3,R4,R5,R6,R7,R8및 B는 각각 위에서 규정된 바와 같다.
- 제 1 항에 있어서, 다음 일반식으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염.식에서 R1,R2,R4,R5,R6,R7,R8및 B는 각각 위에서 규정된 바와 같다.
- 제 1 항에 있어서, 다음 일반식으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염.식에서 R1,R3,R4,R5,R6,R7,R8및 B는 각각 위에서 규정된 바와 같다.
- 다음 일반식(Ⅱ)으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염.식에서 R15는 R1에 관하여 규정된 바와 같고, R16은 R3에 관하여 규정된 바와 같다.
- 다음 일반식(Ⅲ)으로 표시되는 것을 특징으로 하는 프로펜산 유도체 또는 그 약리학적으로 허용가능한 염.식에서 R17은 R1에 관하여 규정된 바와 같고, R18은 R3에 관하여 규정된 바와 같다.
- 다음 일반식(Ⅳ)으로 표시되는 것을 특징으로 하는 아민.식에서 R19및 R20은 동일하거나 상이할 수 있고 각각 임의로 치환된 아릴, 임의로 치환된 아릴알킬, 임의로 치환된 헤테로아릴 또는 임의로 치환된 헤테로아릴 알킬을 나타낸다.
- 다음 일반식으로 표시되는 것을 특징으로 하는 아민.
- 아데노신 길항작용이 효험이 있는 병의 예방 또는 치료방법으로, 특허청구의 범위 제 1 항에 규정된 바의 화합물 또는 그 약리학적으로 허용가능한 염의 약리학적 유효량을 상기 병에 걸렸거나 걸리게 될 대상자에게 투여하는 것을 특징으로 하는 병의 예방 또는 치료방법.
- 제 9 항에 있어서, 아데노신 길항작용이 아데노신 Al 수용체 길항작용인 것을 특징으로 하는 병의 예방 또는 치료방법.
- 제 9 항에 있어서, 상기 병이 산장부전중인 것을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP93-177278 | 1993-06-24 | ||
JP17727893 | 1993-06-24 | ||
JP20290393 | 1993-07-23 | ||
JP93-202903 | 1993-07-23 | ||
JP93-227924 | 1993-08-21 | ||
JP22792493 | 1993-08-21 | ||
JP93-237188 | 1993-08-31 | ||
JP23718893 | 1993-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950000693A true KR950000693A (ko) | 1995-01-03 |
Family
ID=27474760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940014602A KR950000693A (ko) | 1993-06-24 | 1994-06-24 | 프로펜산 유도체 |
Country Status (12)
Country | Link |
---|---|
US (2) | US5541213A (ko) |
EP (1) | EP0630894A1 (ko) |
JP (1) | JP3815691B2 (ko) |
KR (1) | KR950000693A (ko) |
CN (1) | CN1111622A (ko) |
AU (1) | AU683460B2 (ko) |
CA (1) | CA2126020A1 (ko) |
FI (1) | FI942923A (ko) |
HU (1) | HUT71106A (ko) |
NO (1) | NO942372L (ko) |
NZ (2) | NZ260816A (ko) |
TW (1) | TW278074B (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
JPH11513022A (ja) * | 1995-08-02 | 1999-11-09 | スミスクライン・ビーチャム・コーポレイション | エンドセリンレセプターアンタゴニスト |
US6008372A (en) * | 1996-01-16 | 1999-12-28 | Warner-Lambert Company | Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine inhibitors of protein farnesyltransferase |
WO1997028160A1 (en) * | 1996-02-01 | 1997-08-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
WO1997028159A1 (en) * | 1996-02-01 | 1997-08-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
ID18983A (id) * | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
US20060211731A1 (en) * | 1999-05-05 | 2006-09-21 | Les Laboratories Servier | New substituted pyridine or piperidine compounds |
US7183276B2 (en) | 2002-02-28 | 2007-02-27 | Takeda Pharmaceutical Company Limited | Azole compounds |
US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
WO2004039365A1 (en) | 2002-11-01 | 2004-05-13 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
DE10300124A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Verfahren zur Herstellung von Arylalkinen |
JPWO2008010511A1 (ja) * | 2006-07-19 | 2009-12-17 | 武田薬品工業株式会社 | スクリーニング方法 |
EP1939180A1 (en) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
DE102008039082A1 (de) * | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008039083A1 (de) * | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
EP2739144A4 (en) * | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
KR20210083380A (ko) | 2011-07-29 | 2021-07-06 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
JP6006794B2 (ja) * | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス,インコーポレイテッド | 核内輸送調節因子およびその使用 |
IN2014DN09434A (ko) | 2012-05-09 | 2015-07-17 | Karyopharm Therapeutics Inc | |
WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
CN105339358B (zh) | 2013-06-21 | 2019-06-04 | 卡尔约药物治疗公司 | 核转运调节剂及其用途 |
SG10201808624VA (en) | 2014-08-15 | 2018-11-29 | Karyopharm Therapeutics Inc | Polymorphs of selinexor |
US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
EP3397633A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
CN111943900B (zh) * | 2019-05-17 | 2023-11-17 | 宁夏苏融达化工有限公司 | 异噁唑啉衍生物及其在农业中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3542661A1 (de) * | 1985-12-03 | 1987-06-04 | Bayer Ag | Imidazopyridazinalkensaeureamide, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung |
US4743238A (en) * | 1986-03-17 | 1988-05-10 | Malcolm Nicol & Co. | Wetness indicating hot-melt adhesives |
US4769466A (en) * | 1987-02-06 | 1988-09-06 | Pennwalt Corporation | 2-aminoacetamide pyridinyl derivatives |
US4925849A (en) * | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
EP0497258B1 (en) * | 1991-01-29 | 2002-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer |
GB9107513D0 (en) * | 1991-04-10 | 1991-05-29 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
-
1994
- 1994-06-10 US US08/258,634 patent/US5541213A/en not_active Expired - Lifetime
- 1994-06-15 EP EP94109221A patent/EP0630894A1/en not_active Withdrawn
- 1994-06-16 CA CA002126020A patent/CA2126020A1/en not_active Abandoned
- 1994-06-17 FI FI942923A patent/FI942923A/fi not_active Application Discontinuation
- 1994-06-22 NZ NZ260816A patent/NZ260816A/en unknown
- 1994-06-22 NZ NZ272142A patent/NZ272142A/en unknown
- 1994-06-22 NO NO942372A patent/NO942372L/no unknown
- 1994-06-23 AU AU64878/94A patent/AU683460B2/en not_active Ceased
- 1994-06-24 KR KR1019940014602A patent/KR950000693A/ko not_active Application Discontinuation
- 1994-06-24 JP JP16594794A patent/JP3815691B2/ja not_active Expired - Fee Related
- 1994-06-24 CN CN94107564A patent/CN1111622A/zh active Pending
- 1994-06-24 HU HU9401917A patent/HUT71106A/hu unknown
- 1994-07-13 TW TW083106343A patent/TW278074B/zh active
-
1995
- 1995-04-11 US US08/419,941 patent/US5606073A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
TW278074B (ko) | 1996-06-11 |
HUT71106A (en) | 1995-11-28 |
FI942923A0 (fi) | 1994-06-17 |
CN1111622A (zh) | 1995-11-15 |
EP0630894A1 (en) | 1994-12-28 |
AU683460B2 (en) | 1997-11-13 |
NZ260816A (en) | 1996-11-26 |
NZ272142A (en) | 1996-11-26 |
AU6487894A (en) | 1995-01-05 |
JP3815691B2 (ja) | 2006-08-30 |
HU9401917D0 (en) | 1994-09-28 |
FI942923A (fi) | 1994-12-25 |
NO942372D0 (ko) | 1994-06-22 |
JPH07118237A (ja) | 1995-05-09 |
US5606073A (en) | 1997-02-25 |
NO942372L (no) | 1994-12-27 |
CA2126020A1 (en) | 1994-12-25 |
US5541213A (en) | 1996-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950000693A (ko) | 프로펜산 유도체 | |
ATE178067T1 (de) | Camptothecinderivate | |
CA2167673A1 (en) | Condensed benzazepine derivative and pharmaceutical composition thereof | |
KR950701640A (ko) | 에리트로마이신 유도체(eryhromycin derivative) | |
KR960704919A (ko) | 신규인 펩티드 유도체 (novel peptide derivative) | |
DE69232854D1 (de) | Bizyklische fibrinogenantagonisten | |
DE69705829D1 (de) | Meta-substituierte phenylsulphonamidderivate | |
RU93005332A (ru) | Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения | |
KR920002596A (ko) | 아지비사이클로 유도체 | |
KR940005597A (ko) | 4, 1- 벤즈옥사제핀 유도체 및 그의 용도 | |
ATE287393T1 (de) | Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
KR950702831A (ko) | 심장 보호제(cardio-protective agent) | |
KR910007883A (ko) | 퀴놀린 유도체, 그의 제조방법 및 용도 | |
KR920014778A (ko) | 헤테로사이클릭 하이드록실아민 | |
KR950000695A (ko) | 헤테로환식 고리를 함유하는 우레아 유도체 | |
KR970707122A (ko) | 퀴놀린 유도체(quinoline derivative) | |
KR970703301A (ko) | 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative) | |
DK1107751T3 (da) | Lægemiddel indeholdende platinkompleksforbindelser samt anvendelse deraf | |
KR880013896A (ko) | 벤조푸로[3,2-c]퀴놀린 화합물 | |
KR940000443A (ko) | 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 | |
EP0730863A3 (en) | A corneal opacification inhibitory composition comprising a fumagillol derivative | |
KR910007878A (ko) | 디히드로피리딘 유도체 및 의약 조성물 | |
DK378087A (da) | Tetracycliske indolderivater | |
KR890014515A (ko) | 트리사이클릭 아민 유도체 | |
KR910007939A (ko) | 헤테로사이클릭 화합물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |